Theragen Etex

066700 · KOSDAQ · Health Care · SMALL CAP

Back to a net profit.

Theragen Etex reported consolidated results for FY2025: revenue of US$190M (+8.8% year on year), operating profit of US$7.16M (−18.3% year on year) and net income of US$8.23M (from a loss a year earlier).

Earnings(Change of 30% or more in revenue or profit/loss structure (15% for large companies))· FILED 2026-02-26· RCEPT 20260226901339

US$190MRevenue
+8.8%Revenue vs a year earlier
US$7.16MOperating profit

Converted at 1 USD ≈ ₩1,426.93 (filing-date rate, 2026-02-26 close)

What happened

Theragen Etex reported consolidated results for FY2025: revenue of US$190M (+8.8% year on year), operating profit of US$7.16M (−18.3% year on year) and net income of US$8.23M (from a loss a year earlier).

Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.

RevenueUS$190M
Revenue vs a year earlier+8.8%
Operating profitUS$7.16M
Net incomeUS$8.23M
PeriodFY2025 (consolidated)
Filed2026-02-26, Change of 30% or more in revenue or profit/loss structure (15% for large companies)
SourceDART rcept 20260226901339 → open original filing

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-02-26 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.